Association of cytotoxic T-lymphocyte antigen 4 gene polymorphisms with idiopathic thrombocytopenic purpura in a Chinese population

References

• Cines DB, Blanchette VS. Immune thrombocytopenic purpura. N Engl J Med 2002; 346: 995–1008
   PubMed Web of Science ®Google Scholar
• Zhou B, Zhao H, Yang RC, Han ZC. Multi-dysfunctional pathophysiology in ITP. Crit Rev Oncol Hematol 2005; 54: 107–116
   PubMed Web of Science ®Google Scholar
• Teft WA, Kirchhof MG, Madrenas J. A molecular perspective of CTLA-4 function. Annu Rev Immunol 2006; 24: 65–97
   PubMed Web of Science ®Google Scholar
• Collins AV, Brodie DW, Gilbert RJ, Iaboni A, Manso-Sancho R, Walse B, Stuart DI, van der Merwe PA, Davis SJ. The interaction properties of costimulatory molecules revisited. Immunity 2002; 17: 201–210
   PubMed Web of Science ®Google Scholar
• Carreno BM, Bennett F, Chau TA, Ling V, Luxenberg D, Jussif J, Baroja ML, Madrenas J. CTLA-4 (CD152) can inhibit T cell activation by two different mechanisms depending on its level of cell surface expression. J Immunol 2000; 165: 1352–1356
   PubMed Web of Science ®Google Scholar
• Grohmann U, Orabona C, Fallarino F, Vacca C, Calcinaro F, Falorni A, Candeloro P, Belladonna ML, Bianchi R, Fioretti MC, et al. CTLA-4-Ig regulates tryptophan catabolism in vivo. Nat Immunol 2002; 3: 1097–1101
   PubMed Web of Science ®Google Scholar
• Flores-Borja F, Jury EC, Mauri C, Ehrenstein MR. Defects in CTLA-4 are associated with abnormal regulatory T cell function in rheumatoid arthritis. Proc Natl Acad Sci USA 2008; 105: 19396–19401
   PubMed Web of Science ®Google Scholar
• Oaks MK, Hallett KM. Cutting edge: A soluble form of CTLA-4 in patients with autoimmune thyroid disease. J Immunol 2000; 164: 5015–5018
   PubMed Web of Science ®Google Scholar
• Liu MF, Wang CR, Chen PC, Fung LL. Increased expression of soluble cytotoxic T-lymphocyte-associated antigen-4 molecule in patients with systemic lupus erythematosus. Scand J Immunol 2003; 57: 568–572
   PubMed Web of Science ®Google Scholar
• Finck BK, Linsley PS, Wofsy D. Treatment of murine lupus with CTLA4Ig. Science 1994; 265: 1225–1227
   PubMed Web of Science ®Google Scholar
• Lenschow DJ, Ho SC, Sattar H, Rhee L, Gray G, Nabavi N, Herold KC, Bluestone JA. Differential effects of anti-B7-1 and anti-B7-2 monoclonal antibody treatment on the development of diabetes in the nonobese diabetic mouse. J Exp Med 1995; 181: 1145–1155
   PubMed Web of Science ®Google Scholar
• Lundquist LM. Abatacept: A novel treatment for rheumatoid arthritis. Expert Opin Pharmacother 2007; 8: 2371–2379
   PubMed Web of Science ®Google Scholar
• Harper K, Balzano C, Rouvier E, Mattei MG, Luciani MF, Golstein P. CTLA-4 and CD28 activated lymphocyte molecules are closely related in both mouse and human as to sequence, message expression, gene structure, and chromosomal location. J Immunol 1991; 147: 1037–1044
   PubMed Web of Science ®Google Scholar
• Vijayakrishnan L, Slavik JM, Illes Z, Greenwald RJ, Rainbow D, Greve B, Peterson LB, Hafler DA, Freeman GJ, Sharpe AH, et al. An autoimmune disease-associated CTLA-4 splice variant lacking the B7 binding domain signals negatively in T cells. Immunity 2004; 20: 563–575
   PubMed Web of Science ®Google Scholar
• Wang XB, Zhao X, Giscombe R, Lefvert AK. A CTLA-4 gene polymorphism at position −318 in the promoter region affects the expression of protein. Genes Immun 2002; 3: 233–234
   PubMed Web of Science ®Google Scholar
• Harbo HF, Celius EG, Vartdal F, Spurkland A. CTLA4 promoter and exon 1 dimorphisms in multiple sclerosis. Tissue Antigens 1999; 53: 106–110
   PubMedGoogle Scholar
• Ueda H, Howson JM, Esposito L, Heward J, Snook H, Chamberlain G, Rainbow DB, Hunter KM, Smith AN, Di Genova G, et al. Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. Nature 20034;23:506–511.
   Google Scholar
• Maier LM, Anderson DE, De Jager PL, Wicker LS, Hafler DA. Allelic variant in CTLA4 alters T cell phosphorylation patterns. Proc Natl Acad Sci USA 2007; 104: 18607–18612
   PubMed Web of Science ®Google Scholar
• Atabani SF, Thio CL, Divanovic S, Trompette A, Belkaid Y, Thomas DL, Karp CL. Association of CTLA4 polymorphism with regulatory T cell frequency. Eur J Immunol 2005; 35: 2157–2162
   PubMed Web of Science ®Google Scholar
• Bicek A, Zaletel K, Gaberscek S, Pirnat E, Krhin B, Stopar TG, Hojker S. 49A/G and CT60 polymorphisms of the cytotoxic T-lymphocyte-associated antigen 4 gene associated with autoimmune thyroid disease. Hum Immunol 2009; 70: 820–824
   PubMed Web of Science ®Google Scholar
• Jin P, Xiang B, Lin J, Huang G, Zhou WD, Zheng C, Chao C, Zhou ZG. [Association of CTLA-4 + 49A/G and CT60 gene polymorphism with type 1 diabetes and thyroid autoimmunity]. Zhonghua Yi Xue Za Zhi 2009; 89: 1246–1249
   PubMedGoogle Scholar
• Peng J, Liu C, Liu D, Ren C, Li W, Wang Z, Xing N, Xu C, Chen X, Ji C, et al. Effects of B7-blocking agent and/or CsA on induction of platelet-specific T-cell anergy in chronic autoimmune thrombocytopenic purpura. Blood 2003; 101: 2721–2726
   PubMed Web of Science ®Google Scholar
• Zhang XL, Peng J, Sun JZ, Guo CS, Yu Y, Wang ZG, Chu XX, Hou M. Modulation of immune response with cytotoxic T-lymphocyte-associated antigen 4 immunoglobulin-induced anergic T cells in chronic idiopathic thrombocytopenic purpura. J Thromb Haemost 2008; 6: 158–165
   PubMed Web of Science ®Google Scholar
• Pavkovic M, Georgievski B, Cevreska L, Spiroski M, Efremov DG. CTLA-4 exon 1 polymorphism in patients with autoimmune blood disorders. Am J Hematol 2003; 72: 147–149
   PubMed Web of Science ®Google Scholar
• Rodeghiero F, Stasi R, Gernsheimer T, Michel M, Provan D, Arnold DM, Bussel JB, Cines DB, Chong BH, Cooper N, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood 2009; 113: 2386–2393
   PubMed Web of Science ®Google Scholar
• Zeller B, Rajantie J, Hedlund-Treutiger I, Tedgard U, Wesenberg F, Jonsson OG, Henter JI. Childhood idiopathic thrombocytopenic purpura in the Nordic countries: Epidemiology and predictors of chronic disease. Acta Paediatr 2005; 94: 178–184
   PubMed Web of Science ®Google Scholar
• Baroja ML, Luxenberg D, Chau T, Ling V, Strathdee CA, Carreno BM, Madrenas J. The inhibitory function of CTLA-4 does not require its tyrosine phosphorylation. J Immunol 2000; 164: 49–55
   PubMed Web of Science ®Google Scholar
• Waterhouse P, Penninger JM, Timms E, Wakeham A, Shahinian A, Lee KP, Thompson CB, Griesser H, Mak TW. Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science 1995; 270: 985–988
   PubMed Web of Science ®Google Scholar
• Liu B, Zhao H, Poon MC, Han Z, Gu D, Xu M, Jia H, Yang R, Han ZC. Abnormality of CD4(+)CD25(+) regulatory T cells in idiopathic thrombocytopenic purpura. Eur J Haematol 2007; 78: 139–143
   PubMed Web of Science ®Google Scholar